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Abstract
Background: Neurofibromatosis 1 (NF1) is an inherited, multi-system, tumour suppressor disorder with variable
complications that cause psychological distress and social isolation. The study aim was to develop and validate a
disease-specific questionnaire to measure quality of life (QOL) in NF1 that is suitable both as an assessment tool in
clinical practice and in clinical trials of novel therapy.
Methods: The Impact of NF1 on Quality of Life (INF1-QOL) questionnaire was developed by a literature search for
common terms, focus group (n = 6), semi-structured interviews (n = 21), initial drafts (n =50) and final 14 item
questionnaire (n = 50). Bivariate correlations between items, exploratory factor analysis, correlations with severity
and EuroQol were employed.
Results: INF1-QOL showed good internal reliability (Cronbach’s alpha 0.87), mean total INF1-QOL score was 8.64
(SD 6.3), median 7.00, range 0–30 (possible range 0–42); no significant correlations with age or gender. The mean
total EuroQol score was 7.38 (SD 2.87), median 6.5, mean global EuroQol score was 76.34 (SD 16.56), median 80.
Total INF1-QOL score correlated with total EuroQol r = 0.82, p < 0.0001. The highest impact on QOL was moderate
or severe problems with anxiety and depression (32%) and negative effects of NF1 on role and outlook on life
(42%). The mean inter-relater reliability for grading of clinical severity scores was 0.71 (range 0.65-0.79), and
intra-class correlation was 0.92. The mean clinical severity score was 1.95 (SD 0.65) correlating r = 0.34 with
total INF1-QOL score p < 0.05 and correlated 0.37 with total EuroQol score p < 0.01. The clinical severity score
was mild in 17 (34%), moderate in 16 (32%) and 17 (34%) individuals had severe disease.
Conclusions: INF1-QOL is a validated, reliable disease specific questionnaire that is easy and quick to
complete. Role and outlook on life and anxiety and depression have the highest impact on QOL indicating
the variability, severity and unpredictability of NF1. INFI-QOL correlates moderately with clinical severity. The
moderate relationship between INF1-QOL and physician rated severity emphasizes the difference between
clinical and patient perception. INFI-QOL will be useful in individual patient assessment and as an outcome
measure for clinical trials.
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Background
Neurofibromatosis 1 (NF1) is a common, autosomal do-
minantly inherited disease that primarily involves the
nervous system, eye, skin, and bone [1]. NF1 is associated
with an increased frequency of benign and cancerous
tumours and the hallmark lesion is the neurofibroma, a
benign peripheral nerve sheath tumour. The complica-
tions are extensive and range from learning difficulties,
central nervous system tumours, neurovascular disease,
sleep disturbance, hypertension and scoliosis, to neuro-
fibromas causing disfigurement, nerve root and spinal
cord compression and malignancy [1]. The clinical mani-
festations are variable, unpredictable and potentially life
threatening. Disfigurement and social isolation represent
potent causes of psychological distress and there is a 50%
risk of passing on NF1 to an offspring [1, 2].
Advances in molecular biology have facilitated the
development of novel therapy including drugs that have
the potential to treat symptomatic neurofibromas. A
phase 1 study of selumetinib was performed in NF1 chil-
dren and in young adults after preclinical research
showed a reduction in size of plexiform neurofibromas
with mitogen activated protein kinase kinase pathway
(MEK) inhibition [3]. Recent results suggest that selume-
tinib is helpful in treating inoperable, symptomatic plexi-
form neurofibromas [4, 5]. Robust outcome measures
are essential to evaluate the efficacy of the therapy, from
both the clinician’s and the patient’s standpoint. Current
practice is to measure disease progression in NF1 by
clinical and neurological assessment, magnetic reson-
ance imaging and positron emission tomography [1].
The impact of NF1 on the individual’s quality of life
(QOL) is more difficult to evaluate and there is a need
for disease-specific questionnaires in NF1 that will
evaluate health related QOL. QOL is recognised as an
important marker of disease progression, and as an out-
come measure following intervention. QOL may be
assessed using semi-structured interviews, generic or
disease-specific questionnaires. Semi-structured inter-
views were performed in Australian NF1 adults with
varying disease severity and visible neurofibromas [6].
The participants experienced psychological distress re-
lated to learning problems, pain and the cosmetic bur-
den of NF1. They were concerned about the uncertainty
of disease progression and the risk of passing on NF1 to
their offspring. A Brazilian study of NF1 adults used the
generic WHOQOL-100 and semi-structured interviews
[7]. Patients were apprehensive about disease visibility
affecting social relationships. Confusion about distin-
guishing NF1 from contagious diseases and disease
variability were also distressing. Mautner et al. under-
took a variety of physical assessments and generic
psychosocial measures to assess quality of life in NF1 indi-
viduals [8]. They reported that patients had a negative
body image that resulted in low self-confidence and
psychological distress.
Generic questionnaires such as the Short-Form 36
(SF-36) and EuroQol are widely used in clinical practice
and research [9, 10}. However, the SF-36 is lengthy,
which is problematic in NF1 patients who have impaired
sustained attention [1]. Neither of these questionnaires
[9, 10] specifically addresses symptoms related to NF1.
The Skindex questionnaire is useful to evaluate the im-
pact of the skin manifestations of NF1 on QOL but does
not deal with the other significant complications associ-
ated with the disease [11]. Wolkenstein et al. adminis-
tered the SF-36 and Skindex questionnaires to NF1
patients and noted that more visible disease had a
greater impact on physical function, pain, general health
and vitality [11].
At present there is only one disease-specific QOL ques-
tionnaire for NF1 adults reflecting quantitative assessment
of quality of life [12]. The adult version of PedsQL™ was
developed as a module for NF1 adults from PedsQL™ and
integrates generic and disease specific questions. The
adult PedsQL™ has multiple physical, social, emotional,
cognitive domains and assessments of daily functioning.
However, only 15 adults participated in the initial develop-
ment of the questionnaire and there was no independent
clinician rating of physical severity. The self-report instru-
ment comprises 70 items, but omits evaluation of import-
ant problems in NF1, including Bone Health and Sleep
disorders. The large number of questions increases the
risk of missed or inaccurate responses, particularly in
patients with cognitive problems.
Previously, we have worked with patients and clini-
cians to devise a validated, disease-specific questionnaire
for neurofibromatosis 2 (NF2), a rare tumour suppressor
condition, characterised by bilateral vestibular schwan-
nomas and other nervous system tumours [13, 14]. The
questionnaire is simple to complete, correlates well with
clinician-related severity and has been adopted widely by
clinicians to assess quality of life in NF2.
Aims
The aim of this study was to develop and validate a
disease-specific questionnaire to measure QOL in people
with NF1, that is suitable as an assessment tool in clin-
ical practice and in clinical trials, and that is quick and
simple to complete. Furthermore, the goal was to assess
the impact of diagnosis, management and burden of
disease on the individual with NF1.
Methods
Guy’s and St. Thomas’ NHS Foundation Trust (GSTT)
and Central Manchester University Hospitals Founda-
tion Trust (CMFT) are national centres for the diagno-
sis, management and support of approximately 1000
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people with mild and severe NF1 in each centre. Adults
with NF1 were approached when they attended the
clinic and given information sheets identifying the aims
of the projects and inviting them to participate in the
study. Adults (18 years or older) who fulfilled the diag-
nostic criteria for NF1 (NIH Consensus Development
Conference 1987) [15] and attended the National NF1
service at GSTT or CMFT were included. NF1 individ-
uals under 18 years, people who did not fulfil the diag-
nostic criteria for NF1 and patients who were unable to
give informed consent were excluded. Interpreters were
available and support was offered by the clinical nurse
specialist to patients with cognitive and literacy prob-
lems, visual impairment, upper limb weakness, numb-
ness or incoordination.
Ethical Committee approval for the study was obtained
from County Durham and Tees Valley Research and
Ethics Committee. Written informed consent was ob-
tained from every participant.
Disease severity was determined using the Riccardi NF
severity grade classification 1 to 4 [16]. Grades 1 and 2
were amalgamated to ensure adequate numbers in
each group. Grades 1 and 2 were deemed mild, grade
3 moderate and grade 4 severe. Four clinicians (three
neurology consultants and a clinical nurse specialist)
with expertise in NF1 rated the patient clinical prob-
lem list independently.
Development of INF1-QOL questionnaire
The impact of neurofibromatosis one on quality of life
questionnaire was named INF1-QOL and the question-
naire was developed using sequential stages to ensure
robust construction. A comprehensive list of symptoms,
social and emotional difficulties related to NF1 was
produced using a literature review, qualitative interviews
and advice from clinicians and nurses with expertise
in NF1.
As part of routine care, six sequential patients attend-
ing the NF1 service were invited to a focus group session
to discuss symptoms and concerns that could impact on
NF1 QOL. The session was manually recorded and
coded and identifying data were removed. GSTT and
CMFT recruited 21 individuals to participate in qualita-
tive interviews and they were representative of the
general NF1 population as regards age, gender and
disease severity. The in-depth interview was semi-
structured and conducted in a secure private environ-
ment [17]. All interviews were recorded and transcribed,
identifying data were removed and analysis was carried
out using a framework approach [17].
A list of 55 items was generated by these processes
and analysed by a multi-disciplinary panel of NF1 spe-
cialists and a psychologist to produce a pilot question-
naire using the previously proven systematic approach
[13]. The 16 item pilot questionnaire was completed by
50 NF1 participants.
The pilot questionnaire was analysed by the following:
bivariate correlations between items, exploratory factor
analysis and correlations with physician severity scoring.
The pilot questionnaire comprised 16 items that the
participant rated as no problem, mild, moderate or
severe. After completion of the 16 item pilot question-
naire, the questions on interactions with health services
and other people’s attitudes to NF1 were removed due
to redundancy with other items.
The final questionnaire was completed by a further 50
patients. It comprised 14 items that were rated by the
participant in the same way as the pilot questionnaire.
The maximum potential score for the 14 item question-
naire was 42, each item was scored from zero to three,
and the highest score denoted the worst function. A free
text section was included at the end for participants to
provide an explanation and expanded information on
any item that impacted on QOL.
The final 14 item INF1-QOL questionnaire was admin-
istered with a generic measure of QOL. The EuroQol
questionnaires were completed by the 50 NF1 participants
who did the final 14 item INF1-QOL questionnaire. The
EuroQol (EQ 5D) contains a global health score and
covers Mobility, Self-care, Usual Activities, Pain/Discom-
fort, Anxiety and Depression [10]. Physician rated severity
score and EuroQol provided some estimate of external
validity in the 14 item pilot questionnaire.
Participants were offered long-term follow-up in
GSTT or CMFT national NF1 centres as part of routine
clinical care for people with neurofibromatosis 1.
Results
Six individuals attended a focus group, 21 people partici-
pated in the semi-structured interviews, 50 completed
the first version of the questionnaire (16 items) and a
further 50 patients completed the final version (14
items) and the EuroQol. Physician rated severity scores
were available for each stage of testing. The participants
included 44% males and 56% females, the mean age was
38.3 years (SD 14.1) and the range was 18–77 years.
Fifty five items were generated from the literature
search, the NF1 specialists, the patient focus group and
the qualitative interviews. The items were grouped into
eight themes including school difficulties, work issues,
physical problems, emotions and feelings, activities of
daily living and leisure activities, interaction with health
services, other people’s attitude to NF1, and relation-
ships with employers, family and or friends. The 16 item
pilot questionnaire was constructed to reflect these
themes and after completion interactions with health
services and other people’s attitudes to NF1 were
removed due to redundancy with other items. The final
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questionnaire comprised 14 items and a free text section
was provided at the end.
The final version included the following items reflect-
ing the six remaining themes: Vision, Cosmetic appear-
ance, Pain (quality and intensity), Learning Problems,
Behaviour and Personality, Mobility and Walking, Hand
Function, Speech, Bone Health, Breathing, Sleeping,
Role and Outlook on Life, Depression and Anxiety
(Additional file 1).
The final version of the INF1-QOL questionnaire
showed good internal reliability (Cronbach’s alpha 0.87).
The mean total INF1-QOL score was 8.64 (SD 6.3),
median 7.0 with a range of 0–30 (Fig. 1) and there was
no significant correlation with age or gender. The indi-
vidual item responses are shown in Table 1, detailing the
number and percentage of individuals with no problem,
mild, moderate or severe problems for each of the 14
questions. The mean total EuroQol score was 7.38 (SD
2.87), median 6.5, with an observed range of 5–18 and
the mean global EuroQol score was 76.34 (SD 16.56), me-
dian 80, range of 25–100. The correlation of total INF1-
QOL score with total EuroQol was r = 0.82, p < 0.0001.
The individual item responses for the five questions (no
problem, slight, moderate, severe or extreme problems)
are shown in Table 2.
The mean inter-relater reliability for the grading of
clinical severity scores was 0.71 (range 0.65-0.79), and
the intra-class correlation was 0.92. The mean clinical
severity score was 1.95 (SD 0.65) correlated r = 0.34 with
total INF1-QOL score p < 0.05 and correlated 0.37 with
total EuroQol score p < 0.01. The clinical severity score
was averaged across raters and 17 (34%) patients had
mild NF1, 16 (32%) had moderate disease and 17 (34%)
were rated as severe.
Discussion
We have developed a disease specific quality of life
questionnaire that encompasses the wide variation in
phenotype in NF1 adults. All the participants reported
that INF1-QOL was easy to understand and were able
to finish it within ten minutes. INF1-QOL correlated
highly with EuroQol; although EuroQol was quicker
to complete, the INF1-QOL had a broader range of
themes and was disease specific. Moreover, the space
for free text permitted the patient to clarify an answer
and to help us determine whether the problem was
related to NF1. For instance, visual impairment was
due to refraction problems in one individual and not
caused by a co-existing NF1 related optic pathway
glioma. The free text also provided the opportunity to
highlight personal issues that a patient might find dif-
ficult to discuss within a multi-disciplinary clinic.
The highest recorded score was 30 out of a possible
total of 42 and implies that the impact of the disease on
quality of life may be severe in some but not all items.
This emphasizes the broad range and variability of the
NF1 phenotype. Anxiety and depression and role and
outlook on life had the highest impact on QOL. There
were moderate or severe problems in 32% of participants
with anxiety and depression and moderate or severe
problems due to effect of NF1 on role and outlook on
life in 42% of individuals. This is readily explained by a
Fig. 1 Total INF1-QOL score distribution in 50 NF1 participants
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chronic, inherited and unpredictable disease where ill-
ness adjustment is a significant feature.
Pain quality correlated with total INF1-QOL score
rather more than pain intensity but both have a major
impact on quality of life in people with NF1. Bone
dysplasia, benign and malignant peripheral nerve sheath
tumours may cause significant pain and pain intensity
can be helpful in distinguishing benign neurofibromas
from cancerous tumours [1]. Cosmetic problems were
rated as mild in 32% and moderate or severe in 16% of
patients, highlighting that the visible manifestations of
the disease are a potent cause of distress [6–8, 11].
Although participants reported only mild problems in
some domains such as breathing, these symptoms still
impact significantly on quality of life in people with
multiple and unpredictable manifestations of disease.
Importantly, our study was representative of the adult
NF1 population as a whole and the patients were well
distributed for age and gender. The clinician rated dis-
ease severity demonstrated even spread across the three
rankings mild, moderate and severe and there was good
inter-rater reliability. There was a moderate relationship
between clinician rated severity and patient rated quality
of life and likely reflects the difference in disease percep-
tion between patient and clinician. This distinction is
crucial, particularly in the context of evaluating novel
therapy. A drug will be of limited benefit, if for instance,
it reduces tumour size, but the patient perceives no
improvement of quality of life.
Conclusions
INF1-QOL is a validated, reliable disease specific
questionnaire that correlates moderately well with dis-
ease severity. The next stage will be to determine the
reliability of INFI-QOL over time and potentially the
questionnaire could be developed in computerised
form. INFI-QOL is simple and quick to complete and
covers a broad range of themes, representative of
NF1 manifestations. We believe that it will be helpful
in monitoring quality of life in the clinic setting as
well as a disease outcome measure in clinical trials
and therapeutic intervention.
Table 1 The INF1-QOL 14 item questionnaire – responses in 50 NF1 participants
INF1-QOL Question No problem n (%) Mild Problem n (%) Moderate Problem n (%) Severe Problem n (%) Pearson Correlation with Total
INF1-QOL Score (p 2-tailed)
Q1 Vision 24 (48) 20 (40) 5 (10) 1 (2) .380 (.006)
Q2 Cosmetic appearance 26 (52) 16 (32) 4 (8) 4 (8) .623 (<.001)
Q3 Pain quality 25 (50) 20 (40) 4 (8) 1 (2) .810 (<.001)
Q4 Pain Intensity 21 (42) 19 (38) 8 (16) 2 (4) .671 (<.001)
Q5 Learning problems 16 (32) 25 (50) 9 (18) 0 (0) .678 (<.001)
Q6 Behaviour and
personality
27 (54) 18 (36) 4 (8) 1 (2) .569 (<.001)
Q7 Mobility and walking 42 (84) 4 (8) 4 (8) 0 (0) .620 (<.001)
Q8 Weakness, numbness,
clumsiness in hands
37 (72) 11 (24) 2 (4) 0 (0) .698 (<.001)
Q9 Speech 36 (72) 12 (24) 2 (4) 0 (0) .496 (<.001)
Q10 Bones 37 (72) 11 (24) 2 (4) 0 (0) .608 (<.001)
Q11 Breathing 42 (84) 8 (16) 0 (0) 0 (0) .351 (.012)
Q12 Sleeping 22 (44) 19 (38) 8 (16) 1 (2) .598 (<.001)
Q13 Role and outlook
on life
13 (26) 16 (32) 14 (28) 7 (14) .693 (<.001)
Q14 Depression and
anxiety
18 (36) 16 (32) 14 (28) 2 (4) .802 (<.001)
Table 2 European Quality of Life (EQ-5D-5 L) Health Questionnaire – responses in 50 NF1 participants
Questions No problem n (%) Slight problems n (%) Moderate problems n (%) Severe problems n (%) Extreme problems n (%)
Q1 Mobility 40 (80) 8 (16) 1 (2) 1 (2) 0 (0)
Q2 Self-Care 46 (92) 1 (2) 3 (6) 0 (0) 0 (0)
Q3 Usual Activities 37 (74) 7 (14) 4 (8) 1 (2) 1 (2)
Q4 Pain/Discomfort 24 (48) 20 (40) 6 (12) 0 (0) 0 (0)
Q5 Anxiety/Depression 24 (48) 13 (26) 8 (16) 4 (8) 1 (2)
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